Read more
This book examines the construction of an innovation system in Brazil's health industries over the past twenty years. The authors argue that the system has remained active despite the crisis that began in 2014. However, while this crisis has led to cuts in public spending on research and health, it has simultaneously tended to stimulate local production and invention aimed at reducing deficits in the trade in medicines and medical technologies. The contributors highlight a model combining the acquisition of new technologies with social justice and the right to health, and introduce new concepts of the "nationalization" of technologies, innovation through copying and civil society regulation of industrial property and of the medicinal drug market.
List of contents
1. General Introduction.- 2. Knowledge Generation and Laboratory Capacity Building in the Fight against HIV/AIDS in Brazil: Experiences on the Development of a Heat-Stable Formulation Comprising Ritonavir.- 3. Nationalizing Efavirenz: Compulsory Licence, Collective Invention and Neo-Developmentalism in Brazil.- 4. The Introduction of Nucleic Acid Tests (NAT) for Blood Screening in the Brazilian Public Healthcare System: Negotiating and Assembling Technologies for the Nationalization of 'Nat Brasileiro' (2005-2013).- 5. The Innovation System for the Leishmaniasis Therapy in Brazil.- 6. A Consortium in Times of Crisis: Producing Brazilian Sofosbuvir? (2014-2017).- 7. Health Rights and Intellectual Property Rights: Ministry of Health Prior Consent for Pharmaceutical Patents in Brazil.- 8. Polymorph Drug Patents and Their Public Health Impact.- 9. Treatment Activism and Intellectual Property of Drugs in Brazil.- 10. Regulating the Copy Drug Market in Brazil: Testing Generics and Similar Medicines (1999-2015).
About the author
Maurice Cassier is Senior Researcher at the French National Center for Scientific Research.
Marilena Correa is Senior Associate Professor at the Institute of Social Medicine-IMS, Brazil.
Summary
This book examines the construction of an innovation system in Brazil’s health industries over the past twenty years. The authors argue that the system has remained active despite the crisis that began in 2014. However, while this crisis has led to cuts in public spending on research and health, it has simultaneously tended to stimulate local production and invention aimed at reducing deficits in the trade in medicines and medical technologies. The contributors highlight a model combining the acquisition of new technologies with social justice and the right to health, and introduce new concepts of the “nationalization” of technologies, innovation through copying and civil society regulation of industrial property and of the medicinal drug market.
